KPV
Lysine-Proline-Valine (α-MSH tripeptide)
Also known as: Lys-Pro-Val, α-MSH(11–13), C-terminal tripeptide of alpha-MSH
Last updated May 13, 2026
What is KPV?
If you have a chronic inflammatory or gut condition and someone mentioned KPV, here’s what you need to know.
KPV is a tripeptide — three amino acids: lysine, proline and valine. It’s the smallest fragment of alpha-MSH (alpha-melanocyte-stimulating hormone), a peptide your body produces naturally to regulate inflammation and immune response. Researchers found that the entire anti-inflammatory effect of alpha-MSH is concentrated in this three-amino-acid tail — KPV by itself retains the inflammation-suppressing properties without the pigment-stimulating effects of the full molecule.
KPV works by binding to melanocortin receptors (MC1R and MC3R) on immune cells, reducing pro-inflammatory cytokines like TNF-alpha, IL-1 and IL-6. These are the same pathways targeted by biologic drugs for ulcerative colitis and Crohn’s — through a different receptor system. Most studied for inflammatory bowel conditions, but research has also examined skin inflammation, wound healing and antimicrobial activity. As of 2026, no large human clinical trials have been completed.
What Does the Research Actually Show?
Multiple animal models of colitis show KPV reduces inflammation scores, decreases pro-inflammatory cytokines and accelerates mucosal healing. Replicated across multiple research groups. One small human pilot study in active ulcerative colitis (under 30 patients, 8 weeks, not placebo-controlled) showed reduced inflammatory markers and symptom improvement. KPV is most effective when delivered orally or rectally rather than systemically — its small size resists GI degradation. This is the use case the FDA flagged for the July 2026 PCAC review.
Animal data across arthritis, allergic airway inflammation and contact dermatitis models. Mechanism is the same as for IBD applications. Human data outside the gut is essentially absent.
Animal studies and case reports suggest topical KPV may accelerate wound closure and reduce inflammation in conditions like atopic dermatitis. Some compounding pharmacies offer it as a topical cream or serum. Bioavailability and formulation quality data are limited.
It’s worth noting: without controlled human trials at scale, we can’t rule out that practitioner-reported benefits are placebo or coincidental with other interventions. The mechanistic rationale for KPV is among the strongest of any peptide under PCAC review — but sound rationale isn’t proof.
How Is KPV Administered?
| Route | Oral capsule (most evidence for IBD), rectal suppository, subcutaneous injection, topical |
| Dosage range | 200–500 mcg per dose |
| Frequency | 1–2x daily |
| Protocol | Course lengths and reassessment cadence vary by use case and provider; clinical protocols are not standardized |
| Access | Removed from Category 2 effective April 22, 2026; PCAC review scheduled July 23, 2026 |
For phase-by-phase response timing and biomarker tracking (oral and subcutaneous routes), see our What to Expect on KPV →
What Are the Side Effects and Risks?
- Mild GI symptoms (oral use, usually transient).
- Injection site irritation (subcutaneous use).
- Headache (uncommon).
- Pregnancy and breastfeeding are absolute contraindications.
Who Should NOT Use KPV?
If you have an active autoimmune condition managed with biologics or other immunosuppressants: KPV’s anti-inflammatory mechanism overlaps significantly with biologic drugs that target TNF-alpha, IL-1 and IL-6. Layering an unstudied peptide on top of a biologic without coordinated specialist oversight creates an interaction profile no one has data on. Your prescribing rheumatologist or gastroenterologist must be in the loop. “My peptide provider said it’s fine” is not coordination.
If you have a melanoma history or active melanoma: KPV acts on melanocortin receptors. The role of these receptors in melanoma biology is not well characterized, and no human studies have evaluated KPV in patients with melanoma history. The cautious default in this situation is avoidance until that data exists.
If you are pregnant or breastfeeding: No safety data exists. This is not a situation where “probably fine” is an acceptable standard.
If you have inflammatory bowel disease and have not seen a gastroenterologist: KPV is not a substitute for specialist diagnosis and care. IBD requires monitoring for complications that no peptide protocol addresses: strictures, fistulas, dysplasia, malabsorption. If your gastroenterologist is willing to incorporate KPV into your overall plan, that’s one thing. Skipping the specialist entirely is another.
If you have GI symptoms but no clear diagnosis: KPV won’t fix the wrong diagnosis. Chronic gut symptoms can be IBD, IBS, SIBO, celiac, food intolerances, parasites, structural conditions or any combination. The workup matters more than the peptide. Starting an anti-inflammatory therapy before you know what you’re treating can mask symptoms while the underlying problem progresses.
The lag in CRP response is worth understanding before drawing conclusions from a single result.
Before You Start: Get Baseline Labs
We recommend baseline lab work before starting any peptide protocol so you and your provider can track changes. Key markers include CBC, CMP, CRP (C-reactive protein) and ESR (inflammatory markers). For gut applications, also consider fecal calprotectin, vitamin D, B12 and an iron panel.
Ask your provider about ordering these labs, or search for direct-to-consumer lab testing services in your area.
Order at-home labs from Everlywell →Lab recommendations are the same regardless of which service you use.
What You'll Need
If your provider prescribes an injectable protocol, you'll need basic supplies.
- Bacteriostatic Water (30ml)Link coming soon
- Insulin Syringes 29 gauge (100ct)Link coming soon
- Alcohol Prep Pads (200ct)Link coming soon
- Sharps ContainerLink coming soon
Supply links are affiliate links. We may earn a commission at no cost to you. We only link to commodity supplies, never to peptide products.
- 1Based on my specific condition, is KPV appropriate, or would established treatment be a better starting point?
- 2Which administration route do you recommend for me, and why? (Oral for IBD applications has the most evidence support.)
- 3What’s the current compounding availability for KPV given the post-Category 2 / pre-PCAC limbo? On what legal basis is your pharmacy filling these prescriptions?
- 4If I’m currently on a biologic or immunosuppressant, how does KPV interact, and have you coordinated with my specialist?
- 5What baseline labs do you want me to complete before starting? How will we measure response?
- 6Which compounding pharmacy do you use, and is it 503A or 503B?
- 7What does success look like, and at what point would we conclude KPV isn’t working?
Is KPV Legal in 2026?
Not FDA-approved. Removed from Category 2 effective April 22, 2026. PCAC review scheduled for July 23, 2026 — KPV is on the agenda alongside BPC-157, TB-500 and MOTS-C, with the FDA reviewing it for “wound healing and inflammatory conditions.” Compounding cannot resume until after PCAC review and a final FDA determination adds KPV to the 503A bulks list. If approved, it will be available via prescription through licensed compounding pharmacies — it will NOT be available over the counter or FDA-approved.
The FDA accepts public comments through Docket FDA-2025-N-6895. Comments received by July 9, 2026 will be provided to the committee.
How Do I Get KPV Through a Legitimate Provider?
No verified providers currently meet our evaluation criteria for this compound. Subscribe to be notified when that changes.
When provider links go live, we’ll disclose all affiliate relationships here.